Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-330 versus 4F-PCC for reversal of factor Xa inhibitor anticoagulation before urgent surgery
NL-OMON53886Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Factor Xa inhibitor-induced anticoagulation comparing PROTHROMPLEX TOTAL with Standard-of-care 4F-PCC (2 arms). Primary endpoint: Intraoperative effective hemostasis at end of surgery. Started Nov 2022; status: active, not recruiting.
02
Drugs
Prothromplex Total
03
Conditions
Factor Xa inhibitor-induced anticoagulation
Beyond the preview
Go deeper on NL-OMON53886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53886.